E Ang, MK Lawrence, CR Heilmann, JA … - Diabetes Technology & Therapeutics, 2009 - liebertonline.com Abstract Background: Long-term safety and efficacy of AIRÒ inhaled insulin (Eli
Lilly and Co., Indianapolis, IN) (AIR is a registered trademark of Alkermes,
Inc., Cambridge, MA) in patients with diabetes and concomitant lung disease ... Cited by 1 - Related articles - All 2 versions
A de la Pena, M Seger, K Rave, L Heinemann … - Diabetes Technology & Therapeutics, 2009 - liebertonline.com Abstract Background: In order to assess pharmacokinetic (PK) and glucodynamic
(GD) attributes relevant to the end user of an inhaled insulin, this study
examined the exposure and GD effect of doses of AIRÒ inhaled insulin (Eli ... Cited by 1 - Related articles - All 3 versions
L Zhi-hong, C Ying-li, LI Fang-ping, YAN … - Chinese Medical Journal, 2008 - cmj.org Background A new inhalable insulin aerosol (Inh-Ins) was developed in China. The
aim of this multicenter clinical study was to evaluate the efficacy and safety
of this new Inh-Ins as a treatment of type 2 diabetes. Regular porcine ... Related articles - Cached - All 6 versions
C Passey, SP Bhardwaj, DK Majumdar - Current Drug Delivery, 2009 - ingentaconnect.com Abstract: Pulmonary insulin delivery is steadily emerging as a promising
solution for the treatment of diabetes mellitus. The large as well as thin
absorptive area of the lungs has not been explored until now for the ... Related articles - All 2 versions